We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.
News - Cellvizio - May 24, 2018

Mauna Kea Technologies obtains first ever FDA clearance for applications of Cellvizio® Confocal Laser Endomicroscopy in Neurosurgery

Pivotal regulatory milestone in high stakes applications
Cellvizio first-to-market in key neurosurgery field
Provides unique response to unmet needs during brain and spinal surgeries

Mauna Kea Technologies today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of the Cellvizio® 100 series F400 and F800 with a new Confocal MiniprobeTM, the CranioFlexTM, to be used during neurosurgical procedures. This marks the 15th U.S. FDA 510(k) clearance of Cellvizio® and the first-ever FDA clearance for CLE applications in neurosurgery.

The Cellvizio® 100 with the CranioFlexTM provides imaging of tissue internal microstructures and allows the identification of cells and vessels and their organization within the central nervous system during cranial diagnostic and therapeutic procedures such as tumor biopsy and resection. The Cellvizio 100 series F400 model operates at 488 nm and the F800 model at 800 nm, two highly relevant wavelengths commonly used during brain surgery for imaging and navigation.

“This is an important regulatory and business milestone for the Company, opening new avenues for market development and strategic partnerships,” said Sacha Loiseau, Ph.D., Founder and Chief Executive Officer of Mauna Kea Technologies. “It also unlocks a new era in neurosurgery, paving the way toward more precise resection of brain and spinal tumors. Cellvizio® is now the first to market endomicroscopic visualization platform providing neurosurgeons for the first time the ability to perform real-time optical biopsies to help determine, for instance, if the tumor is completely excised. This clearance builds on many years of clinical development and is happening at a time when the neurosurgery community recognizes the potential benefits of real-time digital visualization of nervous system tissue microstructures.”